Nuveen Asset Management LLC Cuts Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Nuveen Asset Management LLC decreased its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 56.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 338,056 shares of the company's stock after selling 436,307 shares during the period. Nuveen Asset Management LLC owned 0.27% of Organogenesis worth $1,082,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ORGO. Millennium Management LLC raised its holdings in shares of Organogenesis by 2.8% in the fourth quarter. Millennium Management LLC now owns 208,420 shares of the company's stock valued at $667,000 after buying an additional 5,765 shares during the last quarter. Rhumbline Advisers increased its position in Organogenesis by 7.1% in the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock valued at $369,000 after acquiring an additional 7,621 shares during the period. American Century Companies Inc. raised its stake in Organogenesis by 10.4% during the 4th quarter. American Century Companies Inc. now owns 98,892 shares of the company's stock valued at $316,000 after acquiring an additional 9,311 shares during the last quarter. Wells Fargo & Company MN raised its stake in Organogenesis by 29.6% during the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after acquiring an additional 9,464 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in Organogenesis by 34.9% during the 4th quarter. MetLife Investment Management LLC now owns 36,593 shares of the company's stock worth $117,000 after acquiring an additional 9,465 shares during the period. Institutional investors and hedge funds own 49.57% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their target price on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Stock Performance

Organogenesis stock traded up $0.15 during trading hours on Friday, reaching $3.03. 946,966 shares of the stock were exchanged, compared to its average volume of 1,144,132. Organogenesis Holdings Inc. has a 52-week low of $2.28 and a 52-week high of $6.71. The stock has a market cap of $384.37 million, a P/E ratio of -50.50 and a beta of 1.85. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm's 50 day moving average is $3.85 and its 200 day moving average is $3.86.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). The firm had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. Analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.